Skip to Content

'
Robert A. Wolff, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Division Head, Clinical and Educational Affairs, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Director, Educational Programs, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Sheikh Zayed Bin Sultan Al Nahyan Distinguished University Chair of Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas, MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 421
Houston, TX 77030
Room Number: FC11.2018
Phone: (713) 745-5476
Fax: (713) 794-1807

Education & Training

Degree-Granting Education

1986 Albany Medical College, Albany, NY, MD
1979 Colgate University, Hamilton, NY, BA, Mathematical Economics

Postgraduate Training

7/1989-6/1992 Fellowship Training Hematology/Oncology, Duke University Medical Center, Division of Hematology/Oncology, Department of Medicine, Durham, NC
6/1986-6/1989 Clinical Residency, Internal Medicine, Duke University Medical Center, Department of Medicine, Durham, NC
6/1983-9/1984 NIH-Summer Student Fellowship Biochemistry/Protein Purification, Department of Biochemistry Albany Medical College, Albany, NY, James Dias, Ph.D.
1/1981-7/1982 Graduate Studies In vitro fertilization / Reproductive Physiology, Division of Reproductive Biology, Department of Population Dynamics, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, Barry Zirkin, Ph.D.

Board Certifications

11/1993 Medical Oncology
1/1989 Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Wolff RA, Fuchs M, Di Bartolomeo M, Hossain AM, Stoffregen C, Nicol S, Heinemann V. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. Cancer 118(17):4132-8, 9/1/2012. e-Pub 12/27/2011. PMID: 22213153.
2. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29(22):3037-43, 8/2011. e-Pub 6/2011. PMCID: PMC3157965.
3. Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: the M. D. Anderson Cancer Center experience. Cancer 117(1):77-85, 1/2011. e-Pub 8/2010. PMID: 20737567.

Last updated: 5/7/2013